Related Experiment Videos
Angiogenesis and cancer: recent advances
William Cáceres1, Samuel González
1San Juan Veterans Affairs Medical Center, 10 Calle Casia, San Juan, Puerto Rico 00921. wcjn@prtc.net
Puerto Rico Health Sciences Journal
|July 18, 2003
Summary
Cancer treatment is evolving with anti-angiogenesis drugs that inhibit new blood vessel formation. These therapies offer new options for malignant diseases, representing a promising advancement in oncology.
Area of Science:
- Oncology
- Vascular Biology
Background:
- Cancer cells require new blood vessels for growth and metastasis.
- Angiogenesis inhibition is an emerging therapeutic strategy in cancer treatment.
Purpose of the Study:
- To review anti-angiogenesis drugs currently in clinical development.
- To discuss the mechanisms of action for these novel cancer therapies.
Main Methods:
- Review of clinical studies on anti-angiogenesis drugs.
- Analysis of drug mechanisms targeting tumor angiogenesis.
Main Results:
- Several anti-angiogenesis agents are in clinical trials, including angiostatin, metalloproteinase inhibitors, thalidomide, tamoxifen, and interferons.
- These drugs target the formation of new blood vessels essential for tumor growth.
Conclusions:
- Anti-angiogenesis therapy presents a promising frontier in cancer treatment.
- Combining these agents with other modalities may improve outcomes in acute settings and for long-term cancer prevention.